Is MYGN or NEOG more undervalued in 2026?

CirclFi compares Myriad Genetics, Inc. (MYGN) and Neogen Corporation (NEOG) using 13 institutional-grade valuation models. MYGN has a Quality of Company score of 6.6/10 while NEOG scores 7.6/10.

Which is a better buy — MYGN or NEOG?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MYGN and NEOG valuations compare?

MYGN at $3.97 and NEOG at $8.97 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MYGN vs NEOG Valuation Comparison 2026 — Intrinsic Value Analysis

MYGN

In Vitro & In Vivo Diagnostic Substances

Myriad Genetics, Inc.

Quality

6.6

out of 10

Value Trap

SAFE

Price

$3.97

Last close

Models

12/13

Active

NEOG

In Vitro & In Vivo Diagnostic Substances

Neogen Corporation

Quality

7.6

out of 10

Value Trap

LOW

Price

$8.97

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	MYGN Fair Value	MYGN Upside	NEOG Fair Value	NEOG Upside
Bayesian DCF	Intrinsic	$0.08	-98.1%	$0.94	-89.5%
Earnings Power Value	Intrinsic	$16.62	+318.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$13.29	+240.0%	$14.98	+67.1%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MYGN vs NEOG — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MYGN vs NEOG — Which Stock Is More Undervalued?

NEOG scores higher with a 7.6/10 quality rating vs MYGN's 6.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Myriad Genetics, Inc. (MYGN) and Neogen Corporation (NEOG) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MYGN currently trades at $3.97 with a QOC of 6.6/10, while NEOG trades at $8.97 with a QOC of 7.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).